Clinical Trial Update: Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK [Phase 1, Phase 2]

View source ↗

Summary

Phase I/IIa trial evaluating AVX001 Gel (1% or 3%) vs vehicle over four weeks for actinic keratoses; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• AVX001 Gel (AVX001)

Snippet

Sponsor: Coegin Pharma AB | Conditions: Actinic Keratoses | Phase 1, Phase 2 | Status: UNKNOWN